ProfileGDS5678 / 1423871_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 77% 75% 78% 78% 79% 79% 77% 76% 76% 77% 76% 76% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0256476
GSM967853U87-EV human glioblastoma xenograft - Control 25.3270877
GSM967854U87-EV human glioblastoma xenograft - Control 34.96575
GSM967855U87-EV human glioblastoma xenograft - Control 45.5696478
GSM967856U87-EV human glioblastoma xenograft - Control 55.4178778
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.2857679
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3293779
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2800477
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1752576
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1689476
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.1590477
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2046276
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1260176
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.052876